Episode

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review

Podcast: Hematologic Oncology Update
Published: Mar 4, 2026
Duration seconds: 1465
Processing state: not_requested
Canonical source: https://hematologic-oncology.captivate.fm/episode/5618-ashitp25-micro1
Audio: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/9ea3045b-1386-4d96-8e72-d7e81baa1700.mp3
JSON: /v1/public/podcasts/hematologic-oncology-update-916423/episodes/immune-thrombocytopenia-microlearning-activity-1-with-dr-hanny-al-samkari-ash-2025-review
Markdown: /podcast/hematologic-oncology-update-916423/immune-thrombocytopenia-microlearning-activity-1-with-dr-hanny-al-samkari-ash-2025-review.md

Actions

POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/immune-thrombocytopenia-microlearning-activity-1-with-dr-hanny-al-samkari-ash-2025-review/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/hematologic-oncology-update-916423/immune-thrombocytopenia-microlearning-activity-1-with-dr-hanny-al-samkari-ash-2025-review.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .